{"id":"placebo-valsartan","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Dizziness"},{"rate":"2-3","effect":"Fatigue"},{"rate":"2-4","effect":"Hyperkalemia"},{"rate":"1-2","effect":"Cough"},{"rate":"1-2","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1069","moleculeType":"Small molecule","molecularWeight":"435.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valsartan is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors on vascular smooth muscle and adrenal tissue. By blocking angiotensin II signaling, it causes vasodilation and reduces sodium and water retention, thereby decreasing blood pressure and cardiac workload. This mechanism also provides cardioprotective and renoprotective effects in hypertension and heart failure.","oneSentence":"Valsartan blocks angiotensin II type 1 receptors, reducing vasoconstriction and aldosterone secretion to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:29.773Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Post-myocardial infarction with left ventricular dysfunction"}]},"trialDetails":[{"nctId":"NCT04649229","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-05-27","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT07465653","phase":"PHASE1","title":"A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-19","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":12},{"nctId":"NCT04153136","phase":"PHASE2","title":"The ENCHANTMENT HIV Study","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-09-11","conditions":"HIV/AIDS, Heart Failure With Preserved Ejection Fraction","enrollment":39},{"nctId":"NCT06142383","phase":"PHASE2","title":"A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-12-12","conditions":"Heart Failure","enrollment":136},{"nctId":"NCT06930885","phase":"PHASE3","title":"Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease","status":"RECRUITING","sponsor":"Hospital do Coracao","startDate":"2025-06-12","conditions":"Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD)","enrollment":7713},{"nctId":"NCT06237309","phase":"PHASE2","title":"REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-04-11","conditions":"Heart Failure","enrollment":89},{"nctId":"NCT06236061","phase":"PHASE3","title":"Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Hypertension","enrollment":718},{"nctId":"NCT05056727","phase":"PHASE3","title":"A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-09-30","conditions":"Renal Insufficiency, Chronic, Hyperkalemia","enrollment":1112},{"nctId":"NCT05764057","phase":"PHASE3","title":"DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-06-12","conditions":"AMI, STEMI, NSTEMI","enrollment":450},{"nctId":"NCT03744975","phase":"PHASE2","title":"PDD in Type 2 Diabetes w/wo Diastolic Dysfunction","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-05-01","conditions":"Diabetes Mellitus, Type 2, Diastolic Dysfunction","enrollment":72},{"nctId":"NCT06643819","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A","status":"RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2024-10-14","conditions":"Essential Hypertension","enrollment":324},{"nctId":"NCT05498181","phase":"PHASE2","title":"Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-10-11","conditions":"Hemodialysis","enrollment":100},{"nctId":"NCT05279742","phase":"PHASE1, PHASE2","title":"Enhancing the Natriuretic Peptide System in HFpEF","status":"ENROLLING_BY_INVITATION","sponsor":"Horng Chen","startDate":"2022-11-04","conditions":"Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases","enrollment":60},{"nctId":"NCT06693674","phase":"PHASE3","title":"Effect of Sacubitril-Valsartan on Cardiac Structure and Function","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-02-03","conditions":"Congenital Heart Disease","enrollment":45},{"nctId":"NCT04113109","phase":"PHASE4","title":"Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-11-01","conditions":"Heart Failure","enrollment":46},{"nctId":"NCT05636774","phase":"NA","title":"Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2022-12-12","conditions":"Patients With Advanced Cancer Receiving Specialized Palliative Care","enrollment":97},{"nctId":"NCT03938389","phase":"PHASE4","title":"The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2020-02-25","conditions":"PreDiabetes, Impaired Glucose Tolerance, Obesity","enrollment":90},{"nctId":"NCT05920005","phase":"PHASE3","title":"Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2023-08-22","conditions":"Hypertension","enrollment":702},{"nctId":"NCT05353166","phase":"PHASE2","title":"REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-06-30","conditions":"Heart Failure","enrollment":59},{"nctId":"NCT03686657","phase":"PHASE1, PHASE2","title":"Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients","status":"NOT_YET_RECRUITING","sponsor":"ARKAY Therapeutics","startDate":"2025-10-10","conditions":"Type 2 Diabetes, High Blood Pressure, Arthritis","enrollment":115},{"nctId":"NCT04164732","phase":"PHASE2","title":"Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-01-08","conditions":"Cardiomyopathy, Hypertrophic","enrollment":46},{"nctId":"NCT04971720","phase":"PHASE2, PHASE3","title":"PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-18","conditions":"Obesity, Cardiovascular Diseases, Hypertension","enrollment":160},{"nctId":"NCT06053580","phase":"PHASE2","title":"Repurposing Valsartan May Protect Against Pulmonary Hypertension","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-02-28","conditions":"Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction","enrollment":60},{"nctId":"NCT05465031","phase":"PHASE4","title":"Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)","status":"RECRUITING","sponsor":"Silesian Centre for Heart Diseases","startDate":"2024-04-17","conditions":"Breast Cancer, Neoplasm, Breast, Breast Diseases","enrollment":600},{"nctId":"NCT06863987","phase":"PHASE3","title":"A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2025-02-05","conditions":"Essential Hypertension","enrollment":342},{"nctId":"NCT03988634","phase":"PHASE3","title":"Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-29","conditions":"Heart Failure With Preserved Ejection Fraction (HFpEF)","enrollment":467},{"nctId":"NCT05593575","phase":"PHASE2","title":"Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-03-22","conditions":"Diabetic Kidney Disease","enrollment":305},{"nctId":"NCT03760588","phase":"PHASE2","title":"Prevention of Cardiac Dysfunction During Breast Cancer Therapy","status":"COMPLETED","sponsor":"Torbjorn Omland","startDate":"2019-01-31","conditions":"Breast Cancer Female, Heart Failure","enrollment":138},{"nctId":"NCT04149990","phase":"PHASE2","title":"Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI","status":"TERMINATED","sponsor":"Jacob Moller","startDate":"2018-10-12","conditions":"Myocardial Infarction, Diastolic Dysfunction","enrollment":51},{"nctId":"NCT05155137","phase":"PHASE3","title":"Polypill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt (PROMOTE)","status":"RECRUITING","sponsor":"Hospital Moinhos de Vento","startDate":"2021-12-20","conditions":"Stroke, Cognitive Decline","enrollment":8518},{"nctId":"NCT06771245","phase":"PHASE3","title":"A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-01-24","conditions":"Mild-to-moderate Essential Hypertension","enrollment":606},{"nctId":"NCT06716970","phase":"PHASE3","title":"QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Wuhan Createrna Science and Technology Co., Ltd","startDate":"2024-12-30","conditions":"Essential Hypertension","enrollment":810},{"nctId":"NCT05508035","phase":"PHASE3","title":"The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction","status":"RECRUITING","sponsor":"John Paul II Hospital, Krakow","startDate":"2023-07-13","conditions":"Heart Failure with Moderately Reduced Ejection Fraction","enrollment":666},{"nctId":"NCT02884206","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-11-23","conditions":"Chronic Heart Failure (CHF)","enrollment":592},{"nctId":"NCT04883528","phase":"PHASE1, PHASE2","title":"Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-08-06","conditions":"Covid19","enrollment":42},{"nctId":"NCT04707261","phase":"PHASE4","title":"Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)","status":"RECRUITING","sponsor":"Xiangtan Central Hospital","startDate":"2021-08-06","conditions":"Anemia, Heart Failure","enrollment":1990},{"nctId":"NCT05269615","phase":"PHASE4","title":"Exercise-induced Erythropoiesis: the Mechanistic of Angiotensin II","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2023-03-20","conditions":"Exercise Physiology","enrollment":80},{"nctId":"NCT05359068","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of SPH3127 In Patients With Mild-moderate Essential Hypertension","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2021-06-10","conditions":"Essential Hypertension","enrollment":957},{"nctId":"NCT05117736","phase":"NA","title":"ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure","status":"TERMINATED","sponsor":"Montreal Heart Institute","startDate":"2022-03-15","conditions":"Systemic Right Ventricle, Heart Failure","enrollment":15},{"nctId":"NCT03917459","phase":"PHASE3","title":"COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-04-16","conditions":"Heart Failure, Heart Failure, Systolic, Erectile Dysfunction","enrollment":27},{"nctId":"NCT03300427","phase":"PHASE4","title":"The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-07-05","conditions":"Heart Failure","enrollment":55},{"nctId":"NCT02468232","phase":"PHASE3","title":"Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-06-15","conditions":"Heart Failure With Reduced Ejection Fraction (HF-rEF)","enrollment":225},{"nctId":"NCT00097786","phase":"PHASE3","title":"Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-01","conditions":"Diabetes Mellitus, Type 2","enrollment":9306},{"nctId":"NCT00241098","phase":"PHASE4","title":"The VALIDATE Study of Valsartan for Patients With Early Stage Heart Failure","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-05","conditions":"Hypertension, Congestive Heart Failure","enrollment":37},{"nctId":"NCT00170976","phase":"PHASE3","title":"A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-04","conditions":"HYPERTENSION","enrollment":403},{"nctId":"NCT00409760","phase":"PHASE3","title":"Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-01","conditions":"Hypertension","enrollment":1930},{"nctId":"NCT02924727","phase":"PHASE3","title":"Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-09","conditions":"Acute Myocardial Infarction","enrollment":5669},{"nctId":"NCT05487261","phase":"PHASE4","title":"Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction","status":"UNKNOWN","sponsor":"Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań","startDate":"2022-12-13","conditions":"Heart Failure","enrollment":260},{"nctId":"NCT04929600","phase":"PHASE4","title":"Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2021-11-28","conditions":"Hypertension, Left Ventricular Hypertrophy","enrollment":120},{"nctId":"NCT01805804","phase":"PHASE4","title":"Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients","status":"TERMINATED","sponsor":"Medical University of Silesia","startDate":"2017-01","conditions":"First Time Dual Chamber Pacemaker Implantation","enrollment":88},{"nctId":"NCT03315832","phase":"PHASE2, PHASE3","title":"Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study","status":"WITHDRAWN","sponsor":"University Hospital, Limoges","startDate":"2023-01-02","conditions":"Aortic Valve Stenosis, Valsartan, Angiotensin Receptor Antagonists","enrollment":""},{"nctId":"NCT02678312","phase":"PHASE2, PHASE3","title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-11-03","conditions":"Pediatric Heart Failure","enrollment":393},{"nctId":"NCT04394117","phase":"PHASE4","title":"Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2020-06-19","conditions":"Coronavirus Disease 2019, COVID-19","enrollment":787},{"nctId":"NCT02130687","phase":"NA","title":"Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2014-06","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":106},{"nctId":"NCT02816736","phase":"PHASE4","title":"EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-03-02","conditions":"Heart Failure","enrollment":365},{"nctId":"NCT05089539","phase":"PHASE2","title":"The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF","status":"UNKNOWN","sponsor":"Chongqing Medical University","startDate":"2021-11-01","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":60},{"nctId":"NCT03066804","phase":"PHASE3","title":"A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-22","conditions":"Heart Failure With Preserved Ejection Fraction","enrollment":2572},{"nctId":"NCT02768298","phase":"PHASE4","title":"Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-07-12","conditions":"Chronic Heart Failure With Reduced Ejection Fraction","enrollment":201},{"nctId":"NCT02970669","phase":"PHASE4","title":"Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-16","conditions":"Heart Failure, Reduced Ejection Fraction","enrollment":140},{"nctId":"NCT04335786","phase":"PHASE4","title":"Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-04-17","conditions":"Acute Respiratory Distress Syndrome, SARS-CoV-2, COVID","enrollment":23},{"nctId":"NCT03893526","phase":"PHASE4","title":"Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Copenhagen","startDate":"2019-01-25","conditions":"Type2 Diabetes","enrollment":12},{"nctId":"NCT01912534","phase":"PHASE2","title":"Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM","status":"COMPLETED","sponsor":"Carelon Research","startDate":"2014-03","conditions":"Hypertrophic Cardiomyopathy","enrollment":211},{"nctId":"NCT02874794","phase":"PHASE4","title":"Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-08-17","conditions":"Heart Failure and Reduced Ejection Fraction","enrollment":465},{"nctId":"NCT01870739","phase":"PHASE2","title":"A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10","conditions":"Hypertension","enrollment":115},{"nctId":"NCT02554890","phase":"PHASE4","title":"Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-04-29","conditions":"Acute Heart Failure","enrollment":887},{"nctId":"NCT03168568","phase":"PHASE4","title":"Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2017-05-04","conditions":"Heart Failure","enrollment":79},{"nctId":"NCT02900378","phase":"PHASE3","title":"randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-20","conditions":"Chronic Heart Failure With Reduced Ejection Fraction","enrollment":621},{"nctId":"NCT02788656","phase":"PHASE4","title":"Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2016-09","conditions":"Congestive Heart Failure","enrollment":4},{"nctId":"NCT00219102","phase":"PHASE3","title":"A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Hypertension, Diabetes","enrollment":336},{"nctId":"NCT02636283","phase":"PHASE2","title":"Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2017-12-31","conditions":"Peripheral Arterial Disease","enrollment":6},{"nctId":"NCT03717688","phase":"PHASE4","title":"The Effects of Neprilysin on Glucagon-like Peptide-1","status":"COMPLETED","sponsor":"Nicolai Jacob Wewer Albrechtsen","startDate":"2018-05-17","conditions":"Diabetes, Heart Failure","enrollment":19},{"nctId":"NCT03791723","phase":"NA","title":"Effect of ARNI in Patients With Persistent AF and Enlarged Left Atrium After Catheter Ablation","status":"UNKNOWN","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2019-06-01","conditions":"Atrial Fibrillation, Cardiac Remodeling, Atrial, Sacubitril/Valsartan","enrollment":90},{"nctId":"NCT02480764","phase":"PHASE3","title":"Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-08-27","conditions":"Essential Hypertension","enrollment":612},{"nctId":"NCT02058823","phase":"PHASE4","title":"Intermittent Hypoxia 2: Cardiovascular and Metabolism","status":"TERMINATED","sponsor":"University Hospital, Grenoble","startDate":"2013-08-07","conditions":"Hypoxia, Sleep Apnea, Obstructive Sleep Apnea","enrollment":12},{"nctId":"NCT02606279","phase":"NA","title":"Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2014-07","conditions":"HIV, Aging, Sarcopenia","enrollment":1},{"nctId":"NCT02639637","phase":"PHASE4","title":"Effect of DPP4 Inhibition on Vasoconstriction","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2015-12","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT02572960","phase":"PHASE4","title":"Physiologic Interactions Between the Adrenal- and the Parathyroid Glands","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2015-10","conditions":"Osteoporosis, Vitamin D Deficiency, Cardiovascular Disease","enrollment":81},{"nctId":"NCT01252238","phase":"NA","title":"Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2010-06","conditions":"Insulin Sensitivity, Aortic Compliance, Diastolic Function","enrollment":24},{"nctId":"NCT01318395","phase":"PHASE3","title":"Aliskiren on Retinal Vasculature Treatment Study","status":"COMPLETED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2010-05","conditions":"Arterial Hypertension","enrollment":56},{"nctId":"NCT03005184","phase":"PHASE2","title":"Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2017-09","conditions":"Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III","enrollment":""},{"nctId":"NCT03393377","phase":"NA","title":"Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-09","conditions":"Atherosclerosis","enrollment":20},{"nctId":"NCT00168779","phase":"PHASE4","title":"Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-09","conditions":"Hypertension","enrollment":1185},{"nctId":"NCT03309618","phase":"NA","title":"Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2012-11","conditions":"Myocardial Infarction","enrollment":36},{"nctId":"NCT01617681","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-11-08","conditions":"Pediatric Hypertension With or Without CKD","enrollment":127},{"nctId":"NCT02495324","phase":"PHASE4","title":"Fimasartan Achieving SBP Target (FAST) Study","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2015-06","conditions":"Essential,Hypertension","enrollment":369},{"nctId":"NCT00446524","phase":"PHASE3","title":"Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Hypertension","enrollment":403},{"nctId":"NCT01785472","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-04","conditions":"Essential Hypertension","enrollment":1438},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00171106","phase":"PHASE4","title":"Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-12","conditions":"Diastolic Dysfunction, Symptomatic Heart Failure","enrollment":150},{"nctId":"NCT01377285","phase":"PHASE4","title":"Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-06","conditions":"Chronic Renal Failure","enrollment":350},{"nctId":"NCT00655330","phase":"NA","title":"Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2008-05","conditions":"Type 2 Diabetes Mellitus, Nephropathy","enrollment":170},{"nctId":"NCT01672476","phase":"PHASE3","title":"A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2012-04","conditions":"Hypertension","enrollment":293},{"nctId":"NCT01400256","phase":"PHASE4","title":"Blood Pressure Lowering in Acute Stroke Trial","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2007-08","conditions":"Stroke, Acute","enrollment":""},{"nctId":"NCT01692301","phase":"PHASE2","title":"Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12","conditions":"Hypertension","enrollment":454},{"nctId":"NCT00878969","phase":"PHASE3","title":"Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3","status":"TERMINATED","sponsor":"Vanderbilt University","startDate":"2010-01","conditions":"Oxidative Stress, Endothelial Dysfunction","enrollment":78},{"nctId":"NCT01193101","phase":"PHASE2","title":"Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08","conditions":"Hypertension","enrollment":389},{"nctId":"NCT01281306","phase":"PHASE2","title":"An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Systolic Hypertension","enrollment":910},{"nctId":"NCT00208767","phase":"PHASE2","title":"Effect of Valsartan on Carotid Artery Disease","status":"COMPLETED","sponsor":"Emory University","startDate":"2005-02","conditions":"Carotid Artery Diseases, Atherosclerosis","enrollment":120},{"nctId":"NCT01876368","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-09","conditions":"Hypertension","enrollment":376},{"nctId":"NCT01663233","phase":"PHASE3","title":"Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Essential Hypertension","enrollment":266}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":433,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Valsartan","Other names:","Diovan","Axudan","Vanatex"],"phase":"marketed","status":"active","brandName":"placebo/valsartan","genericName":"placebo/valsartan","companyName":"Medical University of Silesia","companyId":"medical-university-of-silesia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valsartan blocks angiotensin II type 1 receptors, reducing vasoconstriction and aldosterone secretion to lower blood pressure. Used for Hypertension, Heart failure with reduced ejection fraction, Post-myocardial infarction with left ventricular dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}